452 related articles for article (PubMed ID: 31973017)
21. Immunogenicity of the gene S and Pre-S domains in hepatitis B virions and HBsAg filaments.
Heermann KH; Kruse F; Seifer M; Gerlich WH
Intervirology; 1987; 28(1):14-25. PubMed ID: 2448264
[TBL] [Abstract][Full Text] [Related]
22. Computational Design of a Novel VLP-Based Vaccine for Hepatitis B Virus.
Mobini S; Chizari M; Mafakher L; Rismani E; Rismani E
Front Immunol; 2020; 11():2074. PubMed ID: 33042118
[TBL] [Abstract][Full Text] [Related]
23. Cryo-EM structure of native spherical subviral particles isolated from HBV carriers.
Cao J; Zhang J; Lu Y; Luo S; Zhang J; Zhu P
Virus Res; 2019 Jan; 259():90-96. PubMed ID: 30391399
[TBL] [Abstract][Full Text] [Related]
24. Induction of humoral and cell-mediated immune responses by hepatitis B virus epitope displayed on the virus-like particles of prawn nodavirus.
Yong CY; Yeap SK; Goh ZH; Ho KL; Omar AR; Tan WS
Appl Environ Microbiol; 2015 Feb; 81(3):882-9. PubMed ID: 25416760
[TBL] [Abstract][Full Text] [Related]
25. Divergent preS Sequences in Virion-Associated Hepatitis B Virus Genomes and Subviral HBV Surface Antigen Particles From HBV e Antigen-Negative Patients.
Peiffer KH; Kuhnhenn L; Jiang B; Mondorf A; Vermehren J; Knop V; Susser S; Walter D; Dietz J; Carra G; Finkelmeier F; Zeuzem S; Sarrazin C; Hildt E
J Infect Dis; 2018 Jun; 218(1):114-123. PubMed ID: 29528436
[TBL] [Abstract][Full Text] [Related]
26. Enzyme-linked immunoassay of pre-S gene-coded sequences in hepatitis B vaccines.
Neurath AR; Strick N; Kent SB; Offensperger W; Wahl S; Christman JK; Acs G
J Virol Methods; 1985 Dec; 12(3-4):185-92. PubMed ID: 2422192
[TBL] [Abstract][Full Text] [Related]
27. [Detection of pre-S gene products in HBsAg carriers and in hepatitis B vaccines].
Gerken G; Manns M; Kyriatsoulis A; Hess G; Meyer zum Büschenfelde KH
Z Gastroenterol; 1988 Jul; 26(7):374-9. PubMed ID: 2851893
[TBL] [Abstract][Full Text] [Related]
28. Toolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: a case study with hepatitis B vaccine.
Mulder AM; Carragher B; Towne V; Meng Y; Wang Y; Dieter L; Potter CS; Washabaugh MW; Sitrin RD; Zhao Q
PLoS One; 2012; 7(4):e33235. PubMed ID: 22493667
[TBL] [Abstract][Full Text] [Related]
29. Modulation of the immunogenicity of virus-like particles composed of mutant hepatitis B virus envelope subunits.
Cheong WS; Hyakumura M; Yuen L; Warner N; Locarnini S; Netter HJ
Antiviral Res; 2012 Feb; 93(2):209-218. PubMed ID: 22138713
[TBL] [Abstract][Full Text] [Related]
30. Expression, purification and characterization of the Hepatitis B virus entire envelope large protein in Pichia pastoris.
Han X; Ye LB; Li BZ; Bo G; Cai WJ; Hong Z; She YL; Li Y; Kong LB; Wu ZH
Protein Expr Purif; 2006 Oct; 49(2):168-75. PubMed ID: 16829133
[TBL] [Abstract][Full Text] [Related]
31. A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge.
del Valle JR; Devaux P; Hodge G; Wegner NJ; McChesney MB; Cattaneo R
J Virol; 2007 Oct; 81(19):10597-605. PubMed ID: 17634218
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity of Wild Type and Mutant Hepatitis B Surface Antigen Virus-like Particles (VLPs) in Mice with Pre-Existing Immunity against the Wild Type Vector.
Kingston NJ; Walsh R; Hammond R; Joe CCD; Lovrecz G; Locarnini S; Netter HJ
Viruses; 2023 Jan; 15(2):. PubMed ID: 36851527
[TBL] [Abstract][Full Text] [Related]
33. Expression and immunoactivity of chimeric particulate antigens of receptor binding site-core antigen of hepatitis B virus.
Yang HJ; Chen M; Cheng T; He SZ; Li SW; Guan BQ; Zhu ZH; Gu Y; Zhang J; Xia NS
World J Gastroenterol; 2005 Jan; 11(4):492-7. PubMed ID: 15641132
[TBL] [Abstract][Full Text] [Related]
34. [Interferon-gamma (IFN) induced by purified hepatitis B surface antigen (HBSAG) in HBV vaccines].
Fei GZ
Zhonghua Yi Xue Za Zhi; 1989 May; 69(5):271-3, 18. PubMed ID: 2509004
[TBL] [Abstract][Full Text] [Related]
35. A virus-like particle of the hepatitis B virus preS antigen elicits robust neutralizing antibodies and T cell responses in mice.
Cai X; Zheng W; Pan S; Zhang S; Xie Y; Guo H; Wang G; Li Z; Luo M
Antiviral Res; 2018 Jan; 149():48-57. PubMed ID: 29129705
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis B virus prevalence and vaccine antibody titers in children HIV exposed but uninfected in Botswana.
Baruti K; Lentz K; Anderson M; Ajibola G; Phinius BB; Choga WT; Mbangiwa T; Powis KM; Sebunya T; Blackard JT; Lockman S; Moyo S; Shapiro R; Gaseitsiwe S
PLoS One; 2020; 15(8):e0237252. PubMed ID: 32764801
[TBL] [Abstract][Full Text] [Related]
37. [Hepatitis B vaccines-history, achievements, challenges, and perspectives].
Gerlich WH
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2022 Feb; 65(2):170-182. PubMed ID: 35015108
[TBL] [Abstract][Full Text] [Related]
38. An affordable multideterminant plasma-derived hepatitis B virus vaccine.
Prince AM; Vnek J; Brotman B
IARC Sci Publ; 1984; (63):355-72. PubMed ID: 6085626
[TBL] [Abstract][Full Text] [Related]
39. Breaking Hepatitis B Virus Tolerance and Inducing Protective Immunity Based on Mimicking T Cell-Independent Antigen.
Li X; Ni R
Viral Immunol; 2016 Nov; 29(9):502-509. PubMed ID: 27662269
[TBL] [Abstract][Full Text] [Related]
40. Production and immunological analysis of recombinant hepatitis B vaccine.
Emini EA; Ellis RW; Miller WJ; McAleer WJ; Scolnick EM; Gerety RJ
J Infect; 1986 Jul; 13 Suppl A():3-9. PubMed ID: 2427590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
